Misplaced Pages

AGN-1135

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
A monoamine oxidase inhibitor and the racemic form of rasagiline
This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (September 2024) (Learn how and when to remove this message)
Pharmaceutical compound
AGN-1135
Clinical data
Other namesAGN-1135; Racemic rasagiline; (±)-Rasagiline; (RS)-Rasagiline; N-Propargyl-1-aminoindane
Identifiers
IUPAC name
  • N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H13N
Molar mass171.243 g·mol
3D model (JSmol)
SMILES
  • C#CCNC1CCC2=CC=CC=C12
InChI
  • InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2
  • Key:RUOKEQAAGRXIBM-UHFFFAOYSA-N

AGN-1135 (also known as racemic rasagiline or as N-propargyl-1-aminoindane) is a monoamine oxidase inhibitor (MAOI) that was never marketed. It is the racemic form of rasagiline and is a mixture of the R(+)-enantiomer (rasagiline; TVP-1012) and S(–)-enantiomer (TVP-1022). Like rasagiline, AGN-1135 is a selective monoamine oxidase B (MAO-B) inhibitor. Virtually all of the MAOI activity of AGN-1135 lies in rasagiline, which is several orders of magnitude more potent as an MAO-B inhibitor than the S(–)-enantiomer. In relation to this, enantiopure rasagiline was developed and marketed for use as a pharmaceutical drug rather than AGP-1135.

See also

References

  1. ^ Finberg JP (February 2020). "The discovery and development of rasagiline as a new anti-Parkinson medication". Journal of Neural Transmission. 127 (2): 125–130. doi:10.1007/s00702-020-02142-w. PMID 31974721.
  2. ^ Chen JJ, Swope DM (August 2005). "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease". Journal of Clinical Pharmacology. 45 (8): 878–894. doi:10.1177/0091270005277935. PMID 16027398. S2CID 24350277. Archived from the original on 11 July 2012.
Monoamine metabolism modulators
Non-specific
AAADTooltip Aromatic L-amino acid decarboxylase
MAOTooltip Monoamine oxidase
Phenethylamines
(dopamine, epinephrine,
norepinephrine)
PAHTooltip Phenylalanine hydroxylase
THTooltip Tyrosine hydroxylase
DBHTooltip Dopamine beta-hydroxylase
PNMTTooltip Phenylethanolamine N-methyltransferase
COMTTooltip Catechol-O-methyl transferase
Tryptamines
(serotonin, melatonin)
TPHTooltip Tryptophan hydroxylase
AANATTooltip Serotonin N-acetyl transferase
ASMTTooltip Acetylserotonin O-methyltransferase
Histamine
HDCTooltip Histidine decarboxylase
HNMTTooltip Histamine N-methyltransferase
DAOTooltip Diamine oxidase
See also: Receptor/signaling modulators • Adrenergics • Dopaminergics • Melatonergics • Serotonergics • Monoamine reuptake inhibitors • Monoamine releasing agents • Monoamine neurotoxins


Stub icon

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories: